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Abstract background Buruli Ulcer (BU)–HIV co-infection is an important emerging management challenge
for BU disease. Limited by paucity of scientific studies, guidance for management of this co-infection
has been lacking.
methods Initiated by WHO, a panel of experts in BU and HIV management developed guidance
principles for the management of BU–HIV co-infection based on review of available scientific
evidence, current treatment experience, and global recommendations established for management of
HIV infection and tuberculosis.
results The expert panel agreed that all BU patients should be offered quality provider-initiated
HIV testing and counselling. In areas with high prevalence of malaria and/or bacterial infections, all
patients with HIV co-infection should be started on cotrimoxazole preventative therapy. Combination
antibiotic treatment for BU should be commenced before starting antiretroviral therapy (ART) and
provided for 8 weeks duration. The suggested combination is rifampicin (10 mg/kg daily up to a
maximum of 600 mg/day) plus streptomycin (15 mg/kg daily). An alternative regimen is rifampicin
plus clarithromycin (7.5 mg/kg twice daily up to a maximum of 1000 mg daily) although due to drug
interactions with antiretroviral drugs this regimen should be used with caution. ART should be
initiated in all BU–HIV co-infected patients with symptomatic HIV disease (WHO clinical stage 3 or
4) regardless of CD4 cell count and in asymptomatic individuals with CD4 count ≤500 cells/mm3. If
CD4 count is not available, BU–HIV co-infected individuals with category 2 or 3 BU disease should
be offered ART. For eligible individuals, ART should be commenced as soon as possible within
8 weeks after commencing BU treatment, and as a priority in those with advanced HIV disease
(CD4 ≤ 350 cells/mm3 or WHO stage 3 or 4 disease). All co-infected patients should be actively
screened for tuberculosis before commencing BU treatment and before starting ART. Programmes
should implement a monitoring and reporting system to document the outcomes of BU–HIV
interventions.
conclusions Knowledge of the clinical and epidemiological interactions between BU and HIV
disease is limited. While awaiting more urgently needed evidence, current management practice of
both diseases has been useful to build simple ‘common sense’ preliminary guidance on how to
manage BU–HIV co-infection.
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Introduction
Buruli ulcer (BU) is a necrotizing infection of skin and
soft-tissue caused by Mycobacterium ulcerans. The
disease pathogenesis is mediated through a potent
exotoxin called mycolactone which is both toxic to tissues
and impairs local and systemic immune responses to the
infection (Guarner et al. 2003; Coutanceau et al. 2007).
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BU is the third most common mycobacterial disease
worldwide in immunocompetent people, with the greatest
burden of disease in West and Central Africa (World
Health Organisation 2014a). BU affects mainly children
but can occur in all age groups, and commonly affects
people in resource-limited remote areas with limited
access to health care. Disease severity is described accord-
ing to a WHO classification: Category 1 for single lesions
<5 cm diameter, Category 2 for single lesions 5–15 cm
diameter and Category 3 for single lesions >15 cm diam-
eter, osteomyelitis, multiple lesions or lesions in a critical
site (World Health Organisation 2012). Antibiotics are
now the recommended first-line treatment (World Health
Organisation 2012) but many challenges remain with
respect to early diagnosis and initiation of treatment to
reduce the morbidity, long-term disability and economic
costs associated with the burden of disease (Stienstra
et al. 2005; O’Brien et al. 2013a).
Areas of Africa endemic for BU are also endemic for
HIV with adult HIV prevalence rates between 1% and
5%. Although there is a lack of information on the prev-
alence of BU–HIV co-infection, preliminary evidence sug-
gests that HIV may increase the risk of BU (Johnson
et al. 2008; Christinet et al. 2014; Yeboah-Manu et al.
2013). In the Medecins Sans Frontieres programme in
Akonolinga, Cameroon, the prevalence of HIV is approx-
imately 3–6 times higher in BU treated patients than the
regional estimated HIV prevalence (37% vs. 7% in
women; 20% vs. 5% in men; and 4% vs. 0.7% in chil-
dren; Christinet et al. 2014). Similar data have been
reported from Benin, where patients with BU were eight
times more likely to have HIV infection than those with-
out BU (2.6% vs. 0.3%), and Ghana where HIV preva-
lence was 5 times higher in BU patients (5% vs. 0.9%;
Raghunathan et al. 2005; Johnson et al. 2008).
There is an increasing recognition of BU–HIV co-infec-
tion as an important challenge for the management of BU
disease in settings where the two diseases overlap (O’Bri-
en et al. 2013a); however, guidance for the management
of BU–HIV co-infection has been lacking. To address this
issue, WHO recently issued preliminary guidance on the
management of BU–HIV infection, but it was limited by
the paucity of evidence and experience, and was largely
extrapolated from the experience of TB/HIV co-infection,
which may differ in terms of risks and benefits of recom-
mendations (World Health Organisation 2012). Building
on this work, this article summarises the conclusions of
more recent guidance developed by a panel of clinicians
and technical experts taking into consideration more
recent evidence, preliminary data from ongoing manage-
ment protocols and clinical experience in managing these
two diseases (Tables 1 and 2).
Challenges in the co-treatment of BU–-HIV
HIV may affect the clinical presentation and severity of
BU disease with a reported increased incidence of multi-
ple, larger and ulcerated BU lesions in HIV-infected indi-
viduals (Johnson et al. 2002; Toll et al. 2005; Kibadi
et al. 2010; Komenan et al. 2013; Christinet et al. 2014).
It also appears that the presence and severity of BU may
reflect the level of underlying immune suppression in an
HIV-infected person. In the Medecins Sans Frontieres’
programme in Akonolinga, Cameroon, 79% of patients
with category 2 or 3 BU lesions had a CD4 count ≤500
cells/mm3; vs. 54% of those with category 1 lesions
(P = 0.019) (Christinet et al. 2014) and the main lesion
size was significantly larger with falling CD4 cell counts
(Christinet et al. 2014). These findings need to be con-
firmed with further research.
There is minimal knowledge about the impact of HIV
on BU treatment outcomes such as mortality, cure, recur-
rence, time to healing, long-term disability and the inci-
dence of paradoxical reactions secondary to antibiotic
treatment. Further data from Akonolinga, Cameroon sug-
gested that in BU/HIV co-infected patients a CD4 cell
count above 500 cell/mm3 was associated with a reduc-
tion in the time needed to heal BU lesions by more than
50% compared to those BU/HIV co-infected patients
with a CD4 count 500 cell/mm3 or below (hazard ratio,
2.39; P = 0.001; 95% CI, 1.44–3.98), although HIV
itself was not associated with differences in time to heal-
ing (Christinet et al. 2014). These findings need further
confirmation in other settings.
BU–HIV co-infected patients often present with signifi-
cant immunosuppression. 70% of patients in Akonolinga
have CD4 counts ≤ 500 cells/mm3 at BU diagnosis, and
thus in need antiretroviral therapy (ART) (World Health
Organisation 2013; Christinet et al. 2014). Data from
this routine programme setting also suggest that mortality
in BU patients was significantly higher in those with HIV
co-infection than for those without HIV co-infection
(11% vs. 1%, P < 0.001). Median CD4 cell count at
baseline among the 8 deceased HIV-infected patients was
229 cell/mm3 (IQR 98–378 cell/mm3), death occurred
early with a median time to death post BU diagnosis of
41.5 days (IQR 16.5–56.5 days) and none had received
ART (Christinet et al. 2014).
There is uncertainty about the best way to manage
HIV in patients with active BU, such as when to start
ART, and what the optimal ART regimens are, given the
potential for significant interactions between antiretrovi-
ral drugs and antibiotics used to treat BU. There is also a
critical lack of information to know whether ART will
influence the incidence and severity of paradoxical
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reactions, and to guide the management of these reac-
tions in HIV patients, especially those on ART.
Guiding principles for the management of BU–HIV
co-infection
Buruli ulcer (BU) patients may represent a sentinel group
of patients with a higher prevalence of HIV, and know-
ing the HIV status will affect treatment options and may
influence mortality and BU outcomes. For these reasons,
all BU patients should be offered quality provider-
initiated HIV testing and counselling at their initial con-
tact with the BU treatment centre. Those found to be
HIV positive should be referred to health providers
trained in HIV management. Ideally, this would be inte-
grated within the BU treatment centres to facilitate timely
ART initiation and avoid patient loss to follow-up that
may occur when patients are referred to different centres.
However, if HIV management in BU treatment centres is
not possible, then referral to the nearest HIV treatment
centre will be required. Good co-operation between the
BU and HIV treatment programmes on a local, regional
and national level should be established to ensure the
highest standard of care for BU–HIV co-infected patients.
Combination antibiotic treatment for BU should be
commenced before commencing ART for HIV to minimise
pill burden and avoid drug interactions and side effects in
the early stages of BU treatment, to allow the time needed
for patient preparation for ART, and to follow the usual
principle of HIV care to treat and stabilize any co-infections
prior to commencing ART. Based on experience with
excellent BU outcomes in non-HIV-infected populations
(Chauty et al. 2007; Nienhuis et al. 2010; Sarfo et al.
2010), the recommended combination is rifampicin
10 mg/kg daily up to a maximum of 600 mg/day plus
streptomycin 15 mg/kg daily. If this regimen is not toler-
ated, acceptable or available, then an alternative regimen
is rifampicin 10 mg/kg daily up to a maximum of 600
Table 1 Considerations for drugs used to treat BU and HIV co-infection
Potential concerns Potential benefits
ARV drugs
Efavirenz Contraindicated in children <3 years of age
Reduce clarithromycin levels
Increased toxicity when combined with clarithromycin
Efavirenz levels remain therapeutic when
combined with rifampicin
Once daily administration
Nevirapine Reduction in nevirapine levels when combined with
rifampicin
Twice daily administration
Risk of hypersensitivity particularly at higher CD4 counts
Can be used in children <3 years of age
PI Significant reduction in levels when combined with
rifampicin.
Some can be used with dose adjustments (double dose or
increased boosting ritonavir dose), but with increased
toxicity when combined with rifampicin
Raltegravir Limited data on safety and effectiveness when combined with
rifampicin.
Limited availability/high cost




Rifampicin Significantly reduces levels of nevirapine and PI Most effective drug for BU
Oral administration
Streptomycin Injectable agent
Increased toxicity (renal and vestibular)
Contraindicated in pregnancy
Most published evidence of effectiveness as
companion drug to rifampicin in HIV-negative
patients.




Can be used in pregnancy
Moxifloxacin Limited data on use in HIV positive patients
Not recommended in pregnancy or children <18 years of
age
Limited availability/high cost
No interaction with ART drugs
Once daily administration
Oral administration
Active against M. tuberculosis
PI, protease inhibitor.
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mg/day plus clarithromycin 7.5 mg/kg twice daily (up to a
maximum of 1000 mg daily); this was effective in obser-
vational studies in non-HIV-infected patients (Chauty
et al. 2011). However, due to potential drug interactions
with ART, this combination should be used with caution.
At this stage, there is no evidence that the duration of BU
antibiotic treatment needs to be prolonged beyond the
standard recommended 8 week course for BU–HIV
co-infected patients (World Health Organisation 2012).
As currently recommended for all HIV-infected individ-
uals, a CD4 cell count should be determined for all
BU–HIV positive patients to assess the level of HIV-
associated immune suppression. If the CD4 cell count is
equal to or less than 350 cells/mm3, then prophylactic
cotrimoxazole (960 mg tablet daily) should be com-
menced immediately to reduce mortality, morbidity and
HIV disease progression (Suthar et al. 2012). If a CD4
count is not available and the patient has advanced HIV
disease (WHO clinical stages 3 or 4) they should receive
cotrimoxazole prophylaxis regardless of CD4 cell count
(World Health Organisation 2006). In areas with high
prevalence of malaria and/or severe bacterial infections,
cotrimoxazole should be commenced regardless of CD4
cell count in all BU–HIV-infected patients and continued
for life (World Health Organization 2014b).
If patients are already receiving ART, then this should
be continued. All patients with active BU disease who are
known or diagnosed as HIV positive but not on ART
Table 2 Guidance for the co-management of BU and HIV
Guidance Basis for the Guidance
HIV Testing
All BU patients should be offered quality provider-initiated HIV testing and




Cotrimoxazole preventive therapy (one 960 mg tablet daily) should be commenced
immediately for all patients with a CD4 count <350 cells/mm3 or if CD4 count is
not available and the patient has advanced HIV disease (WHO clinical stages 3 or
4). In settings with highly prevalent malaria and/or severe bacterial infections,
cotrimoxazole preventive therapy is initiated in all individuals regardless of CD4
cell count.
WHO Guidance for Cotrimoxazole
prophylaxis
BU treatment
Combination antibiotic treatment for BU should be commenced before commencing
ART and provided for 8 weeks duration.
The recommend combination is rifampicin 10 mg/kg daily up to a maximum of
600 mg/day plus streptomycin 15 mg/kg daily.
An alternative regimen is rifampicin 10 mg/kg daily up to a maximum of 600 mg/
day plus clarithromycin 7.5 mg/kg twice daily up to a maximum of 1000 mg daily.
This regimen should be used with caution (see text).
Based on WHO Guidance for ART
initiation in TB co-infected patients
Based on WHO guidance for BU
treatment
Based on WHO guidance for BU
treatment
Antiretroviral therapy
If patients are already receiving ART then this should be continued.
ART should be recommended to all patients meeting the eligibility criteria as per
the current WHO Consolidated guidelines for ART.
If CD4 count is not available, those in WHO category 2 or 3 BU disease should be
offered ART.
For eligible individuals, ART should be commenced as soon as possible after the
start of BU treatment, preferably within 8 weeks, and as a priority in those with
advanced HIV disease (CD4 < 350 cells/mm3 or WHO stage 3 or 4 disease).
All children <5 years of age should be commenced on ART within 8 weeks of the
start of BU treatment. ART regimens should follow those recommended in the
current WHO consolidated guidelines for ART.
Based on WHO Guidance for ART
initiation in TB co-infected patients
WHO Guidance for ART
Expert opinion based on preliminary
observational data
Based on WHO Guidance for ART
initiation in TB co-infected patients
Based on WHO Guidance for ART
initiation in TB co-infected patients and
children
Tuberculosis
All patients should be actively screened for tuberculosis before commencing BU
treatment and before starting ART.
Best Practice
Monitoring and evaluation
Programmes should implement a monitoring and reporting system to monitor and
evaluate the outcomes of BU–HIV interventions.
Best Practice
ART, antiretroviral therapy.
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should initiate ART if they have a CD4 cell count equal
to or below 500 cells/mm3, have advanced HIV disease
(WHO clinical stage 3 or 4) or have other concomitant
clinical conditions that meet the eligibility criteria for
commencing ART consistent with current WHO recom-
mendations (i.e. pregnancy, active TB, HIV/HBV co-
infection with severe liver disease, HIV serodiscordant
couples; World Health Organisation 2013). This aims to
reduce HIV-associated mortality and morbidity, which is
increased in patients with CD4 ≤ 500 cells/mm3, and
HIV transmission (World Health Organisation 2013).
Programmatic evidence also suggests that mortality is
increased in HIV-infected patients with BU if ART is not
commenced (Christinet et al. 2014). Furthermore, as the
immune system plays an important role in curing BU dis-
ease and in healing lesions, optimisation of immunity
with ART may be important to combat BU disease and
potentially improve treatment outcomes (healing times,
cure rates, long-term disability and recurrence rates).
If a CD4 count is not available, those in WHO clini-
cal stage 3 or 4 HIV disease should be initiated on
ART. Preliminary evidence suggests that a high propor-
tion of patients with category 2 and 3 BU disease are
likely to have significant immunosuppression, and there-
fore in the absence of CD4 counts those with WHO
category 2 or 3 BU disease should also be offered ART
(Christinet et al. 2014). Those whose CD4 count is not
available with WHO clinical stage 1 and 2 HIV disease
and with WHO category 1 BU disease should not be
offered ART.
Antiretroviral therapy (ART) should begin as soon as
possible after the start of BU treatment, preferably within
8 weeks, and as a priority in those with advanced HIV dis-
ease (CD4 < 350 cells/mm3 or WHO stage 3 or 4 disease).
Patients with advanced HIV are at immediate risk of fur-
ther life-threatening opportunistic infections and delay in
ART initiation may result in significant HIV-associated
morbidity and mortality (Lewden et al. 2014). This risk
may further be increased by an increased risk of bacterial
sepsis from secondarily infected BU lesions. In BU–HIV
co-infected patients with CD4 ≤ 500 cells/mm3 healing
times are significantly more prolonged than among HIV
positive individuals with CD4 > 500 cells/mm3 (Christinet
et al. 2014). Therefore, early reconstitution of immunity
with advanced BU disease may be important. Further-
more, this recommendation also takes into account the
fact that in routine programmes, there may be delays in
ART initiation while patients wait for assessment, training
and availability of ART after completing their BU treat-
ment. Also, as patients may receive BU treatment a signifi-
cant distance from ART centres, they may be lost to HIV
care if ART initiation is delayed (Rosen & Fox 2011).
Patients with CD4 cell counts >500 cells/mm3 should
not commence ART until the CD4 count has fallen to or
below 500 cells/mm3 or other criteria for ART have been
met (World Health Organisation 2013). In patients with
CD4 cell counts >500 cells/mm3, there is no evidence
supporting reduced HIV-associated morbidity and mor-
tality with ART initiation in BU patients. Furthermore,
any potential benefit to BU treatment outcomes by early
restoration of immune function following initiation of
ART early during BU antibiotic treatment is possibly out-
weighed by the potential risks of increased side effects,
pill burden and adherence difficulties. For patients with
less advanced HIV disease (CD4 counts >500 cells/mm3)
and less advanced BU disease (WHO category 1) there is
a risk of reduced BU treatment efficacy due to potential
drug interactions, especially between efavirenz and clari-
thromycin, which favours the delay in initiation of ART.
It is also possible that early initiation of ART will lead to
an increased incidence of paradoxical reactions associated
with immune reconstitution when combining BU antibi-
otic treatment and ART and this may lead to undesired
consequences, especially if lesions are in sensitive areas
(e.g. the face).
All patients should be actively screened for tuberculosis
(TB) before commencing BU treatment and before start-
ing ART (Getahun et al. 2011; World Health Organisa-
tion 2011). As most BU–HIV co-infected patients live in
highly endemic areas for TB, there is an important risk of
TB-co-infection. As HIV-infected patients have a higher
risk of TB reactivation, especially when severely immuno-
suppressed, there is therefore a risk of co-existent active
TB disease. Therefore, it is important to exclude active
TB disease prior to commencing BU treatment, as BU
treatment regimens are not adequate to treat active TB,
which may result in TB-related mortality and morbidity
and the development of drug resistant TB.
Finally, approaches to support adherence to drug treat-
ments for BU and HIV should be integrated, and pro-
grammes should implement a monitoring and reporting
system to monitor and evaluate the outcomes of BU–HIV
interventions.
Antiretroviral treatment and BU treatment
interactions
There are a number of important issues regarding the use
of antiretroviral drugs in patients receiving antibiotic
treatment for BU (Table 1). Firstly, as recommended for
TB/HIV patients on ART using rifampicin containing reg-
imens, the non-nucleoside reverse transcriptase inhibitor
(NNRTI) component of the ART regimen should be
efavirenz (Bonnet et al. 2013; World Health Organisation
1044 © 2014 John Wiley & Sons Ltd
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2013). If this option is not available or appropriate then
nevirapine can be used, but the lead-in dose of nevirapine
should be omitted in the presence of rifampicin at the
start of treatment. Additionally, caution should be exer-
cised in the use of nevirapine particularly in patients with
high or unknown CD4 cell counts at initiation due to a
potential increased risk of hypersensitivity and Stevens
Johnson’s syndrome (Shubber et al. 2013). Close moni-
toring during the initial weeks of therapy is recom-
mended when nevirapine is initiated in these patients. An
alternative, if available, is for an integrase inhibitor such
as raltegravir to replace the nevirapine during the 8-week
BU treatment (Grinsztejn et al. 2014).
There are concerns about significantly reduced levels of
protease inhibitor (PI) medications and increased toxicity
when they are used with rifampicin and therefore they
are ideally avoided during BU antibiotic treatment. If the
patient is already receiving a PI-based regimen, and is
NNRTI-na€ıve and not infected with HIV-2, change the
PI-based regimen to an NNRTI-based regimen using ef-
avirenz. If the patient is not NNRTI-na€ıve or infected
with HIV-2, then the recommended PI regimen to use is
lopinavir (LPV)/ritonavir (RTV) at either double dose
800 mg/200 mg twice daily or standard LPV dose with
increased dose of RTV (400 mg/400 mg), but this combi-
nation in higher doses is frequently associated with high
levels of toxicity and requires close clinical and labora-
tory monitoring. Again an alternative, if available, is for
an integrase inhibitor such as raltegravir to replace the PI
during the 8-week BU treatment.
Efavirenz can reduce clarithromycin levels by up to
39% (Kuper & D’Aprile 2000) which likely further com-
pounds the known significant reduction of clarithromycin
levels when co-administered with rifampicin (Wallace
et al. 1997; Alffenaar et al. 2010). Although the clinical
consequences of these interactions are unknown, it could
potentially lead to reduced effectiveness of the rifampicin/
clarithromycin regimen for BU treatment, with secondary
treatment failure and drug resistance. Increased toxicity is
also reported when the 2 drugs are combined with 46%
of patients reported to develop a rash (Bristol-Myers-
Squibb 2010). Therefore, this combination should be
used with caution. An alternative that avoids this interac-
tion is rifampicin 10 mg/kg daily up to a maximum of
600 mg/day plus moxifloxacin 400 mg daily. Fluoroqui-
nolones have good in vitro activity against M. ulcerans
and combined with rifampicin perform as well as rifam-
picin and streptomycin combinations in the mouse model
(Ji et al. 2006, 2007), have been successfully used in Aus-
tralian non-HIV BU patients (Gordon et al. 2010; O’Bri-
en et al. 2012; Friedman et al. 2013) and are included in
WHO guidelines as an acceptable alternative agent
(World Health Organisation 2012). Furthermore, moxi-
floxacin combined with rifampicin may have benefits in
reducing the risk of rifampicin resistant TB if used in
patients with undetected active drug sensitive TB (O’Brien
et al. 2013b), although this needs to be assessed against
the potential risk of fluoroquinolone resistance develop-
ing in the less likely scenario of undetected rifampicin
resistant TB being present. As experience using moxiflox-
acin in BU/HIV co-infection is limited, its use should be
further studied and evaluated.
Finally, the use of the antiretroviral drug tenofovir in
those being treated with streptomycin may increase the
risk of renal toxicity. (Nelson et al. 2007) Therefore any
additional factors that may decrease renal function (e.g.
dehydration, use of non steroidal anti-inflammatory
drugs) should be avoided and renal function closely mon-
itored when using this drug combination.
Children
All children <5 years of age should be commenced on
ART as soon as possible within 8 weeks of the start of
BU treatment. For children ≥5 years of age, recommenda-
tions for the timing of ART initiation are the same as for
adults. Efavirenz is not approved for clinical use in chil-
dren <3 years of age. Therefore, in this age-group if initi-
ating ART while on BU treatment with rifampicin,
nevirapine should be used instead of efavirenz at a dose of
200 mg/m2. An alternative is to use a triple NRTI ART
regimen. If already on a PI-based ART regimen when
commencing BU treatment with rifampicin, LPV/RTV can
be continued but the dose of RTV should be increased to
achieve a 1:1 ratio with LPV. Alternative options include
either replacing the LPV/RTV with nevirapine at a dose of
200 mg/m2 or using a triple NRTI regimen.
Pregnancy
Efavirenz is no longer contraindicated during the first
trimester of pregnancy and can be used in ART regi-
mens (World Health Organisation 2013). As streptomy-
cin and moxifloxacin are not recommended during
pregnancy, the preferred BU treatment regimen is rifam-
picin 10 mg/kg daily up to a maximum of 600 mg/day
plus clarithromycin 7.5 mg/kg twice daily (up to a max-
imum of 1000 mg daily).
Research agenda
There are many important questions that need to be
addressed to better understand the epidemiological, clinical
and treatment implications of the interaction between BU
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disease and HIV infection, such as an improved under-
standing of the burden of BU in HIV-infected patients
and the relative risk of BU in HIV-infected vs. non-HIV-
infected populations. Clinical questions that need to be
answered include an improved understanding of the effect
of HIV on BU disease patterns, severity and mortality
rates stratified by levels of immune suppression, and an
understanding of the effect of BU on HIV clinical disease.
More information is required to clarify the effect of
HIV on BU treatment outcomes such as mortality, rate of
healing, cure, recurrence and long-term disability. It
needs to be determined if and which patients will benefit
from ART during BU treatment looking at both BU and
HIV treatment outcomes, and the optimal timing of ART
commencement. Research is also required to explore the
effectiveness and safety of drugs used for BU treatment in
HIV-infected patients on ART. For instance, assessing the
effectiveness and safety in HIV-infected patients of BU
treatment regimens that combine rifampicin and moxi-
floxacin (O’Brien et al. 2013b) as well as investigating
the pharmacokinetic, clinical and safety outcomes of rif-
ampicin and clarithromycin regimens in patients receiving
efavirenz. The incidence, severity, predictors (including
ART), management and outcomes of paradoxical reac-
tions during the antibiotic treatment of BU in HIV-
infected patients, all need to be better characterised in
order to better understand the role of immune reconstitu-
tion and its risks and benefits in co-infected patients.
Finally, on an operational level, research is required to
assess the integration of HIV diagnosis and treatment in
BU treatment centres to determine best models of care
for co-infected patients.
Important steps required to answer these questions
include the development and implementation of a
research agenda with WHO and groups experienced in
HIV and BU care, and strengthening research capacity
within BU treatment programmes (O’Brien et al. 2013a).
This could potentially involve the implementation of pro-
spective multicentric BU–HIV cohorts to improve the
power of the research and allow the sharing of treatment
experience.
Conclusions
There are many important challenges involved in the
emerging clinical scenario of treating patients co-infected
with BU and HIV. Scientific studies to guide practice are
currently lacking and research into these issues is eagerly
awaited. While awaiting more evidence, current practice
for management of both diseases allows for simple ‘com-
mon sense’ preliminary guidance on how to respond
when these diseases are combined.
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